- Home
- GOSS vs PEO Comparison
GOSS vs PEO Comparison
Compare GOSS & PEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- PEO
- Stock Information
- Founded
- GOSS 2015
- PEO 1929
- Country
- GOSS United States
- PEO United States
- Employees
- GOSS N/A
- PEO N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- PEO Finance/Investors Services
- Sector
- GOSS Health Care
- PEO Finance
- Exchange
- GOSS Nasdaq
- PEO Nasdaq
- Market Cap
- GOSS 585.9M
- PEO 577.0M
- IPO Year
- GOSS 2019
- PEO N/A
- Fundamental
- Price
- GOSS $2.26
- PEO $21.00
- Analyst Decision
- GOSS Strong Buy
- PEO
- Analyst Count
- GOSS 6
- PEO 0
- Target Price
- GOSS $8.60
- PEO N/A
- AVG Volume (30 Days)
- GOSS 4.0M
- PEO 35.4K
- Earning Date
- GOSS 11-06-2025
- PEO 01-01-0001
- Dividend Yield
- GOSS N/A
- PEO 5.93%
- EPS Growth
- GOSS N/A
- PEO N/A
- EPS
- GOSS N/A
- PEO N/A
- Revenue
- GOSS $40,237,000.00
- PEO N/A
- Revenue This Year
- GOSS N/A
- PEO N/A
- Revenue Next Year
- GOSS $34.10
- PEO N/A
- P/E Ratio
- GOSS N/A
- PEO N/A
- Revenue Growth
- GOSS N/A
- PEO N/A
- 52 Week Low
- GOSS $0.66
- PEO $19.22
- 52 Week High
- GOSS $3.60
- PEO $23.80
- Technical
- Relative Strength Index (RSI)
- GOSS 40.01
- PEO 37.54
- Support Level
- GOSS $2.32
- PEO $21.47
- Resistance Level
- GOSS $2.61
- PEO $21.73
- Average True Range (ATR)
- GOSS 0.20
- PEO 0.32
- MACD
- GOSS -0.08
- PEO -0.07
- Stochastic Oscillator
- GOSS 0.00
- PEO 2.69
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About PEO Adams Natural Resources Fund Inc.
Adams Natural Resources Fund Inc is a non-diversified U.S. equity fund that invests in liquid energy and other natural resources stocks. The Fund's investment objectives are preservation of capital, reasonable income, and opportunity for capital gain. A majority of its assets are invested in petroleum or natural resources industries or industries connected to them. It has broad flexibility to invest in stocks of varying capitalizations and predominantly invests in stocks found in the S&P 500 Energy and S&P 500 Materials sectors.